AYTU Biopharma awards 15,000 restricted shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Disbrow Jarrett reported acquisition or exercise transactions in this Form 4 filing.
Jarrett Disbrow, Chief Business Officer of AYTU Biopharma, reported a grant of 15,000 shares of common stock as restricted stock. The award increases his direct holdings to 76,568 shares and vests over time starting July 28, 2027 in quarterly installments.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 15,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.
Key Figures
Key Terms
restricted stock financial
vesting financial
quarterly installments financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did AYTU’s Jarrett Disbrow report on this Form 4?
Was Jarrett Disbrow’s AYTU stock grant made under a Rule 10b5-1 trading plan?
What type of security did AYTU’s Chief Business Officer receive in this Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.